NCT00131911View on ClinicalTrials.gov

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

October 31, 2010

Study Completion Date

April 30, 2013

Conditions
GastrinomaGlucagonomaInsulinomaMetastatic Gastrointestinal Carcinoid TumorNeuroendocrine TumorPancreatic Polypeptide TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaSomatostatinomaWDHA Syndrome
Interventions
DRUG

sorafenib tosylate

400 mg given orally

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00131911 - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter